Gilead Sciences (GILD) closed the most recent trading day at $118.30, moving -2.71% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.64%. Meanwhile, ...

Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...

On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping ...

KIEV, UKRAINE - 2019/01/16: In this photo illustration, the Edwards Lifesciences Medical device company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA ...

Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening ...

The biotech earned an important fast-track review designation from a major regulator. This should speed the development (and potentially, commercialization) of one of its investigational treatments.

Madison, Wis.-based Exact Sciences saw shares increase 12 percent after Minnetonka, Minn.-based UnitedHealthcare said it would cover the company’s colon cancer screening test Cologuard, according to a ...

Exact Sciences Corp (NASDAQ:EXAS) reported fourth-quarter financial results after the market close on Wednesday. Here’s a look at the key details from the quarter. Q4 Earnings: Exact Sciences reported ...